Ping Zhou
Fudan University, China
Title: Isolation and characterization of a hyperbranched proteoglycan from Ganoderma lucidum for anti diabetes
Biography
Biography: Ping Zhou
Abstract
Inhibition of protein tyrosine phosphatase 1B (PTP1B) activity has been considered as a promising therapy approach to treat type-2 diabetes. In this work, a novel PTP1B activity inhibitor, named FYGL (Fudan-Yueyang-G. lucidum), was screened from the fruiting bodies of Ganoderma lucidum and showed an efficient PTP1B inhibitory potency with IC50=5.12±0.05 μg/mL. The type-2 diabetic animals treated orally by FYGL showed an obvious decrease in the plasma glucose level and comparable with those treated by metformin, a clinic drug. The toxicity of FYGL is very low. FYGL is a water soluble hyperbranched proteoglycan with molecular weight (Mη) of 105. In addition, it was also found that FYGL could protect kidney against the renal functional and morphologic injuries by increasing the activities of antioxidants and inhibiting the accumulation of oxidation. The results indicate that FYGL may serve as a drug candidate or a health care food for the diabetic therapy and renal functional protection.
Speaker Presentations
Speaker PPTs Click Here